Chugai Pharmaceutical Net Cash Flow 2020-2025 | CHGCY

Chugai Pharmaceutical net cash flow for the twelve months ending March 31, 2025 was $-0.869B, a 58.75% increase year-over-year.

  • Chugai Pharmaceutical annual net cash flow for 2024 was $0.538B, a 67.96% decline from 2023.
  • Chugai Pharmaceutical annual net cash flow for 2023 was $1.679B, a 578.4% decline from 2022.
  • Chugai Pharmaceutical annual net cash flow for 2022 was $-0.351B, a 169.6% decline from 2021.

Chugai Pharmaceutical Net Cash Flow 2020-2025 | CHGCY

  • Chugai Pharmaceutical annual net cash flow for 2024 was $0.538B, a 67.96% decline from 2023.
  • Chugai Pharmaceutical annual net cash flow for 2023 was $1.679B, a 578.4% decline from 2022.
  • Chugai Pharmaceutical annual net cash flow for 2022 was $-0.351B, a 169.6% decline from 2021.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$67.2B
Daiichi Sankyo, - (DSNKY)$46.3B
Takeda Pharmaceutical (TAK)$45.6B
BeOne Medicines - (ONC)$33.5B
Sandoz Group AG (SDZNY)$26B
Summit Therapeutics (SMMT)$19.9B
Merck (MKKGY)$16.9B
Shionogi (SGIOY)$14.3B
United Therapeutics (UTHR)$13.4B
Neurocrine Biosciences (NBIX)$13.3B
Orion OYJ (ORINY)$11.4B
IPSEN (IPSEY)$10.8B
Stevanato Group S.p.A (STVN)$7.7B
Corcept Therapeutics (CORT)$7.2B
Grifols, S.A (GRFS)$7.2B
Ionis Pharmaceuticals (IONS)$6.6B
Madrigal Pharmaceuticals (MDGL)$6.5B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.2B
Hypermarcas (HYPMY)$3B
Crinetics Pharmaceuticals (CRNX)$2.7B
Catalyst Pharmaceuticals (CPRX)$2.6B
NewAmsterdam Pharma (NAMS)$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2B
Ocular Therapeutix (OCUL)$1.9B
Endo (NDOI)$1.8B
ARS Pharmaceuticals (SPRY)$1.7B
BioCryst Pharmaceuticals (BCRX)$1.7B